Q-Med Pays To Shut Down Genzyme Injection IP Fight

Law360, New York (February 15, 2011, 3:14 PM ET) -- Medical device manufacturer Q-Med AB has settled Genzyme Corp.'s patent infringement suit over a group of cosmetic injection products licensed to Medicis Pharmaceutical Corp., agreeing to make a lump sum payment to Genzyme in order to end the fight.

Under the terms of the deal that Q-Med announced Tuesday, Genzyme agreed to dismiss the case and release Medicis and Q-Med from any liability related to the suit, which had accused Medicis of infringing Genzyme's U.S. Patent Number 5,399,351 by marketing Sweden-based Q-Med's Restylane and Perlane products...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required